Chemomab Therapeutics Ltd.
CMMB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $16 | $27 | $25 | $34 |
| - Cash | $7 | $5 | $8 | $6 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $9 | $21 | $17 | $28 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2 | -$2 | -$3 | -$3 |
| % Margin | – | – | – | – |
| Net Income | -$2 | -$2 | -$3 | -$3 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.28 | -0.36 | -0.58 | -0.63 |
| % Growth | 22.2% | 37.9% | 7.9% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |